Exact Mass: 481.12459220000005
Exact Mass Matches: 481.12459220000005
Found 226 metabolites which its exact mass value is equals to given mass value 481.12459220000005
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Yersiniabactin
C21H27N3O4S3 (481.1163622000001)
A member of the class of thiazolidines that is (4S)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid which is substituted at position 2 by a (1S)-1-hydroxy-1-{(4R)-2-[(4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl group. A siderophore found in the gram-negative bacterium species, Yersinia enterocolitica and Yersinia pestis. D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
Talampicillin
C24H23N3O6S (481.13074980000005)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08557
Rosuvastatin
C22H28FN3O6S (481.16827600000005)
Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
6-(Methylsulfonyl)hexyl glucosinolate
6-(Methylsulfonyl)hexyl glucosinolate is present in crucifers. Present in crucifers
(3R,5R)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
C22H28FN3O6S (481.16827600000005)
Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-
C23H26F3N3O3S (481.1646882000001)
Talampicillin
C24H23N3O6S (481.13074980000005)
Yersiniabactin
C21H27N3O4S3 (481.1163622000001)
2-(4-Methoxyphenyl)-2,2-dimethylethyl glucosinolate
C18H27NO10S2 (481.10763219999995)
6-Hydroxydelphinidin 3-glucoside
2,3-di(acetyloxy)-4-anilino-1-[1,2-di(acetyloxy)ethyl]-4-oxobutyl acetate
C22H27NO11 (481.15840320000007)
(1E)-5-methoxy-6-hydroxycinnamenyl-(1->6)-5,6-dihydrosanguinarine|maclekarpine E
(4Z)-5-{6-O-[(2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]-beta-glucopyranosylsulfanyl}pent-4-enenitrile
C22H27NO9S (481.1406452000001)
Rosuvastatin
C22H28FN3O6S (481.16827600000005)
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 2802
Ala Cys Cys Trp
C20H27N5O5S2 (481.14535320000005)
Ala Cys Trp Cys
C20H27N5O5S2 (481.14535320000005)
Ala Trp Cys Cys
C20H27N5O5S2 (481.14535320000005)
Cys Ala Cys Trp
C20H27N5O5S2 (481.14535320000005)
Cys Ala Trp Cys
C20H27N5O5S2 (481.14535320000005)
Cys Cys Ala Trp
C20H27N5O5S2 (481.14535320000005)
Cys Cys Glu Lys
Cys Cys Glu Gln
C16H27N5O8S2 (481.13009819999996)
Cys Cys Lys Glu
Cys Cys Gln Glu
C16H27N5O8S2 (481.13009819999996)
Cys Cys Trp Ala
C20H27N5O5S2 (481.14535320000005)
Cys Asp Met Asn
C16H27N5O8S2 (481.13009819999996)
Cys Asp Asn Met
C16H27N5O8S2 (481.13009819999996)
Cys Glu Cys Lys
Cys Glu Cys Gln
C16H27N5O8S2 (481.13009819999996)
Cys Glu Lys Cys
Cys Glu Gln Cys
C16H27N5O8S2 (481.13009819999996)
Cys Lys Cys Glu
Cys Lys Glu Cys
Cys Met Asp Asn
C16H27N5O8S2 (481.13009819999996)
Cys Met Asn Asp
C16H27N5O8S2 (481.13009819999996)
Cys Met Gln Thr
Cys Met Thr Gln
Cys Asn Asp Met
C16H27N5O8S2 (481.13009819999996)
Cys Asn Met Asp
C16H27N5O8S2 (481.13009819999996)
Cys Gln Cys Glu
C16H27N5O8S2 (481.13009819999996)
Cys Gln Glu Cys
C16H27N5O8S2 (481.13009819999996)
Cys Gln Met Thr
Cys Gln Thr Met
Cys Ser Ser Trp
C20H27N5O7S (481.16311120000006)
Cys Ser Trp Ser
C20H27N5O7S (481.16311120000006)
Cys Thr Met Gln
Cys Thr Gln Met
Cys Trp Ala Cys
C20H27N5O5S2 (481.14535320000005)
Cys Trp Cys Ala
C20H27N5O5S2 (481.14535320000005)
Cys Trp Ser Ser
C20H27N5O7S (481.16311120000006)
Asp Cys Met Asn
C16H27N5O8S2 (481.13009819999996)
Asp Cys Asn Met
C16H27N5O8S2 (481.13009819999996)
Asp Met Cys Asn
C16H27N5O8S2 (481.13009819999996)
Asp Met Asn Cys
C16H27N5O8S2 (481.13009819999996)
Asp Asn Cys Met
C16H27N5O8S2 (481.13009819999996)
Asp Asn Met Cys
C16H27N5O8S2 (481.13009819999996)
Glu Cys Cys Lys
Glu Cys Cys Gln
C16H27N5O8S2 (481.13009819999996)
Glu Cys Lys Cys
Glu Cys Gln Cys
C16H27N5O8S2 (481.13009819999996)
Glu Lys Cys Cys
Glu Gln Cys Cys
C16H27N5O8S2 (481.13009819999996)
Lys Cys Cys Glu
Lys Cys Glu Cys
Lys Glu Cys Cys
Met Cys Asp Asn
C16H27N5O8S2 (481.13009819999996)
Met Cys Asn Asp
C16H27N5O8S2 (481.13009819999996)
Met Cys Gln Thr
Met Cys Thr Gln
Met Asp Cys Asn
C16H27N5O8S2 (481.13009819999996)
Met Asp Asn Cys
C16H27N5O8S2 (481.13009819999996)
Met Met Asn Ser
Met Met Ser Asn
Met Asn Cys Asp
C16H27N5O8S2 (481.13009819999996)
Met Asn Asp Cys
C16H27N5O8S2 (481.13009819999996)
Met Asn Met Ser
Met Asn Ser Met
Met Gln Cys Thr
Met Gln Thr Cys
Met Ser Met Asn
Met Ser Asn Met
Met Thr Cys Gln
Met Thr Gln Cys
Asn Cys Asp Met
C16H27N5O8S2 (481.13009819999996)
Asn Cys Met Asp
C16H27N5O8S2 (481.13009819999996)
Asn Asp Cys Met
C16H27N5O8S2 (481.13009819999996)
Asn Asp Met Cys
C16H27N5O8S2 (481.13009819999996)
Asn Met Cys Asp
C16H27N5O8S2 (481.13009819999996)
Asn Met Asp Cys
C16H27N5O8S2 (481.13009819999996)
Asn Met Met Ser
Asn Met Ser Met
Asn Ser Met Met
Gln Cys Cys Glu
C16H27N5O8S2 (481.13009819999996)
Gln Cys Glu Cys
C16H27N5O8S2 (481.13009819999996)
Gln Cys Met Thr
Gln Cys Thr Met
Gln Glu Cys Cys
C16H27N5O8S2 (481.13009819999996)
Gln Met Cys Thr
Gln Met Thr Cys
Gln Thr Cys Met
Gln Thr Met Cys
Ser Cys Ser Trp
C20H27N5O7S (481.16311120000006)
Ser Cys Trp Ser
C20H27N5O7S (481.16311120000006)
Ser Met Met Asn
Ser Met Asn Met
Ser Asn Met Met
Ser Ser Cys Trp
C20H27N5O7S (481.16311120000006)
Ser Ser Trp Cys
C20H27N5O7S (481.16311120000006)
Ser Trp Cys Ser
C20H27N5O7S (481.16311120000006)
Ser Trp Ser Cys
C20H27N5O7S (481.16311120000006)
Thr Cys Met Gln
Thr Cys Gln Met
Thr Met Cys Gln
Thr Met Gln Cys
Thr Gln Cys Met
Thr Gln Met Cys
Trp Ala Cys Cys
C20H27N5O5S2 (481.14535320000005)
Trp Cys Ala Cys
C20H27N5O5S2 (481.14535320000005)
Trp Cys Cys Ala
C20H27N5O5S2 (481.14535320000005)
Trp Cys Ser Ser
C20H27N5O7S (481.16311120000006)
Trp Ser Cys Ser
C20H27N5O7S (481.16311120000006)
Trp Ser Ser Cys
C20H27N5O7S (481.16311120000006)
6-(Methylsulfonyl)hexyl glucosinolate
silybin (mixture of silybin a and silybin b)
C25H21O10 (481.11346660000004)
Bifeprunox Mesylate
C25H27N3O5S (481.1671332000001)
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Bifeprunox mesylate is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pKis of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC50 of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox mesylate is an antipsychotic for the research of schizophrenia[1][2].
methyl 2-[[3-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-hydroxy-1-naphthyl]azo]benzoate
C26H19N5O5 (481.13861240000006)
1H-Pyrrolo[2,3-b]pyridine, 1-[(4-Methylphenyl)sulfonyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(2-thiazolyl)-
1-(METHOXYCARBONYL)-4-PIPERIDINECARBOXYLIC ACID
C23H29Cl2N3O4 (481.15350140000004)
6-[2-[6-(2-dimethylaminoethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]acetyl]-2,3-dimethoxy-benzoic acid
C23H28ClNO8 (481.15033580000005)
Diethyl thiophosphoryl-(Z)-2-(2-aminothiazol-4-yl)-2-(tert-butoxycarbonyl)isopropoxyiminoacetate
C17H28N3O7PS2 (481.11062280000004)
1-Biotinylamino-3,6,9-trioxaundecane-11-bromide
C18H32BrN3O5S (481.12459220000005)
(E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
C22H28FN3O6S (481.16827600000005)
2-[[4-[(2,6-Dimethyl-4-morpholinyl)sulfonyl]phenyl]-oxomethyl]imino-3,4-dimethyl-5-thiazolecarboxylic acid ethyl ester
C21H27N3O6S2 (481.13412020000004)
(3r,5r,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
C22H28FN3O6S (481.16827600000005)
Enloplatin [mart.]
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent > C1450 - Platinum Compound
Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-
C23H26F3N3O3S (481.1646882000001)
Cefepime conjugate acid
C19H25N6O5S2+ (481.13277800000003)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DE - Fourth-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3-Amino-4-hydroxybenzoate-adenylate
C17H18N6O9P- (481.0872848000001)
6-[5-[[(5-cyano-4-oxo-6-phenyl-1H-pyrimidin-2-yl)thio]methyl]-2-oxo-1,3-dihydroimidazol-4-yl]-6-oxohexanoic acid ethyl ester
C23H23N5O5S (481.14198280000005)
N-[1-[(4-bromoanilino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide
N-[2-[(2-furanylmethylamino)-oxomethyl]phenyl]-4-methyl-3-(1-piperidinylsulfonyl)benzamide
C25H27N3O5S (481.1671332000001)
4-[[1-[(3,4-Dichlorophenyl)methyl]-3-indolyl]-(3-methyl-5-oxo-1,2-dihydropyrazol-4-yl)methyl]-5-methyl-1,2-dihydropyrazol-3-one
3-(1,3-benzodioxol-5-ylmethyl)-7-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-2-sulfanylidene-1H-quinazolin-4-one
C24H23N3O6S (481.13074980000005)
N-[3-[(2,4-dimethylphenyl)sulfamoyl]-4-methylphenyl]-3-oxo-4H-1,4-benzothiazine-6-carboxamide
C24H23N3O4S2 (481.11299180000003)
N-(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide
2-[(4-ethoxyphenyl)sulfonylamino]-N-[2-(4-morpholinyl)phenyl]benzamide
C25H27N3O5S (481.1671332000001)
Ethyl 4,5-dimethyl-2-[[2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3-yl)acetyl]amino]thiophene-3-carboxylate
C24H23N3O4S2 (481.11299180000003)
N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-[[4-[3-(dimethylamino)propyl]-5-pyridin-4-yl-1,2,4-triazol-3-yl]thio]acetamide
(1S,9R,10R,11R)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
1-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-(3-chlorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(2-methylphenyl)sulfonylamino]ethyl]-3-oxanyl]urea
C22H28ClN3O5S (481.1438108000001)
(1R,9S,10S,11S)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
C22H32BrN3O4 (481.15760520000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
C23H23F4N3O4 (481.16246060000003)
1-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
1-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
C22H28FN3O6S (481.16827600000005)
(6R,7S)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C19H25N6O5S2+ (481.13277800000003)
(3-oxo-1H-2-benzofuran-1-yl) (2S,5S,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
C24H23N3O6S (481.13074980000005)
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-methoxybenzoate
C18H20N5O9P (481.0998600000001)
GSK598809
GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pKi of 8.9.
SQLE-IN-1
SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT[1]. SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT[1].
UC2288
C20H18ClF6N3O2 (481.09916699999997)
UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].
(r)-{[(2s,4s)-2-amino-1,4-dihydroxy-4-(5-hydroxypyridin-2-yl)butylidene]amino}[(2s,3s,4s,5s)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]acetic acid
4-(hydroxymethyl)-5,6-dimethoxy-3-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-4,8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-undecaen-18-ol
C28H23N3O5 (481.16376280000003)
{[2-amino-1,4-dihydroxy-4-(5-hydroxypyridin-2-yl)butylidene]amino}[5-(4-formyl-2-hydroxyimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid
2-methoxy-4-[(1e)-2-[(23r)-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21)-octaen-23-yl]ethenyl]phenol
(4s)-2-[(1s)-1-hydroxy-2-methyl-1-[(4r)-2-[(4r)-2-[(1e)-6-oxocyclohexa-2,4-dien-1-ylidene]-1,3-thiazolidin-4-yl]-1,3-thiazolidin-4-yl]propan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid
C21H27N3O4S3 (481.1163622000001)
(2r,6s)-4-(hydroxymethyl)-5,6-dimethoxy-3-oxa-1,7,17-triazaoctacyclo[12.12.2.1²,⁶.0⁷,²⁸.0⁸,¹³.0¹⁵,¹⁹.0²⁰,²⁷.0²¹,²⁶]nonacosa-4,8(13),9,11,14(28),15(19),17,20(27),21(26),22,24-undecaen-18-ol
C28H23N3O5 (481.16376280000003)
[(z)-[(4s)-4-hydroxy-7-[(r)-methanesulfinyl]-1-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}heptylidene]amino]oxysulfonic acid
[(e)-(7-methanesulfonyl-1-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}heptylidene)amino]oxysulfonic acid
5,6,7-trihydroxy-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-(3,4,5-trihydroxyphenyl)-1λ⁴-chromen-1-ylium
(4s)-2-[(1s)-1-hydroxy-1-[(2r,4r)-2-[(4r)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid
C21H27N3O4S3 (481.1163622000001)
(r)-{[(2r,4s)-2-amino-1,4-dihydroxy-4-(5-hydroxypyridin-2-yl)butylidene]amino}[(2s,3r,4s,5r)-5-(4-formyl-2-hydroxyimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid
(10s)-10-{[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-8-ethyl-1,6,11-trihydroxy-9,10-dihydrotetracene-5,12-dione
C26H27NO8 (481.17365820000003)
(4r)-2-[(1s)-1-hydroxy-1-[(2r,4r)-2-[(4r)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid
C21H27N3O4S3 (481.1163622000001)
10-[(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy]-8-ethyl-1,6,11-trihydroxy-9,10-dihydrotetracene-5,12-dione
C26H27NO8 (481.17365820000003)
{[2-amino-1,4-dihydroxy-4-(5-hydroxypyridin-2-yl)butylidene]amino}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]acetic acid
(4s)-2-(1-hydroxy-1-{2-[2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl)-4-methyl-5h-1,3-thiazole-4-carboxylic acid
C21H27N3O4S3 (481.1163622000001)